Regulus Therapeutics Appoints Denis Drygin, Ph.D., as Chief Scientific Officer
LA JOLLA, Calif., Aug. 3, 2020 /PRNewswire/ — Regulus Therapeutics Inc. (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs (the “Company” or “Regulus”), today announced the appointment of Denis Drygin, Ph.D.,…
Comments Off on Regulus Therapeutics Appoints Denis Drygin, Ph.D., as Chief Scientific Officer